Biotech Veteran Expands Healthcare Banking Practice
Boston, June 26, 2017 – Baird, an employee-owned, international financial services firm, today announced that Ryan Daws has joined the firm’s Global Investment Banking business as a Managing Director on its Global Healthcare team. Daws will focus on the biotechnology and pharmaceuticals sector, continuing the expansion of the firm’s global healthcare franchise. He will be based in Baird’s Boston office.
With nearly 20 years of healthcare experience, Daws most recently served as chief financial officer at Concert Pharmaceuticals, where he was an integral part of finance, business development and investor relations efforts. Prior to that, he was a healthcare investment banker with Stifel and before that, Cowen. Daws earned a Bachelor of Science in Business Administration with concentrations in finance and organizational management as well as an International MBA from the University of South Carolina.
“We are thrilled to have Ryan join Baird,” said Brian Doyal, Co-Head of Global Investment Banking. “Ryan’s experience as an investment banker and as a CFO gives him deep sector knowledge and a unique perspective covering clients. Ryan is a tremendous addition to our healthcare team and further enhances our coverage of the biotechnology and pharmaceutical sectors.”
“I’m excited to join Baird and return to investment banking,”said Daws.“Baird’s global Healthcare team has extensive industry knowledge and an exceptional track record of delivering successful outcomes for clients. I look forward to the opportunities ahead as we continue to build Baird’s biotechnology platform.”
Baird’s Global Healthcare Investment Banking group has established a strong track record and market share momentum to date, including:
- A senior healthcare team with more than 150 years of collective industry experience;
- More than 64 M&A transactions completed since 2010;
- Approximately $20 billion in capital raised for clients in 90 IPOs, follow-on offerings and other financing transactions since 2010; and
- Experience advising public and private companies and private equity sponsors on healthcare M&A transactions worth more than $12 billion in aggregate.
More broadly, Baird’s Global Investment Banking platform continues to expand. 2016 marked the fourth consecutive year of record revenues for the global investment banking business, up 22 percent from 2015.
About Baird Global Investment Banking
Baird is a leading global investment bank focused on the middle market. Approximately 270 investment banking professionals in the U.S., Europe and Asia provide corporations, entrepreneurs, private equity and venture capital firms with in-depth market knowledge and extensive experience in merger and acquisition, debt advisory and equity financing transactions. Since 2012, Baird has completed nearly 430 advisory transactions representing more than $113 billion in transaction value and 518 financings raising more than $135 billion. Committed to being a great place to work, Baird ranked No. 4 on FORTUNE’s 100 Best Companies to Work For in 2017 – its 14th consecutive year on the list.
Baird is an employee-owned, international wealth management, capital markets, private equity and asset management firm with offices in the United States, Europe and Asia. Established in 1919, Baird has more than 3,400 associates serving the needs of individual, corporate, institutional and municipal clients. Baird has $171billion in client assets. Committed to being a great place to work, Baird ranked No. 4 on FORTUNE’s 100 Best Companies to Work For in 2017 – its 14th consecutive year on the list. Baird is the marketing name of Baird Financial Group. Baird’s principal operating subsidiaries are Robert W. Baird & Co. in the United States and Robert W. Baird Group Ltd. in Europe. Baird also has an operating subsidiary in Asia supporting Baird’s investment banking and private equity operations. For more information, please visit Baird’s Web site at www.rwbaird.com.
For additional information, contact:
Baird Public Relations